The United States Food & Drug Administration (USFDA) has completed a Good Manufacturing Practice (GMP) inspection of Dr. Reddy’s API facility in Srikakulam, Andhra Pradesh. The inspection, which took place between November 10th and November 14th, 2025, concluded with zero observations. This signifies compliance with USFDA standards and supports the continued supply of APIs from this facility.
USFDA Inspection Concludes
Dr. Reddy’s Laboratories has announced the successful completion of a USFDA inspection at its API (Active Pharmaceutical Ingredient) manufacturing facility located in Srikakulam, Andhra Pradesh. The inspection was conducted between November 10th and November 14th, 2025.
Zero Observations
The USFDA’s inspection of the Srikakulam API facility concluded with zero observations. This outcome indicates that the facility adheres to the required Good Manufacturing Practice (GMP) standards set by the USFDA. The absence of observations is a positive indicator for the quality and compliance of the facility’s manufacturing processes.
Source: BSE